Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sildenafil oral spray - Aspargo Laboratories

X
Drug Profile

Sildenafil oral spray - Aspargo Laboratories

Alternative Names: ASP-001; ASP-002; BANDOL

Latest Information Update: 01 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Farmalider
  • Developer Aspargo Laboratories
  • Class Antihypertensives; Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Pyrazoles; Pyrimidinones; Small molecules; Sulfonamides
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Erectile dysfunction

Most Recent Events

  • 31 Jul 2024 In July 2024, Aspargo Labs plans to file an NDA application for ASP 001 for the treatment of erectile dysfunction (ED) in the US
  • 31 Jul 2024 Efficacy data from a phase I trial in Erectile Dysfunction released by Aspargo Labs
  • 01 Dec 2023 Aspargo Laboratories completes enrollment in a phase I pharmacokinetic/bioequivalence trial for Erectile dysfunction

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top